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INTRODUCTION   
Bioadhesive drug delivery formulations were introduced 
in 1947 when gum tragacanth was mixed with dental 
adhesive powder to apply penicillin to the oral mucosa. 
In recent years delivery of therapeutic agents via 
Mucoadhesive drug delivery system has become highly 
interesting. Certain drugs have lack of efficacy due to 
decreased bioavailability, GI intolerance, unpredictable 
and erratic absorption or pre-systemic elimination of 
other potential route for administration. The recent 
development in the drug delivery has intensified the 
investigation of mucosal drug delivery. Such route 
includes oral, buccal, ocular, nasal and pulmonary 
routes
1,2
. Mucoadhesive drug delivery systems are 
delivery systems, which utilized the property of 
bioadhesion of certain polymers, which become adhesive 
on hydration and hence can be used for targeting a drug 
to particular region of the body for extended period of 
time
3
. The ability to maintain a delivery system at a 
particular location for an extended period of time has 
great appeal for both local as well as systemic drug 
bioavailability
4
. 
Among the various routes of drug delivery, the oral route 
is perhaps the one mostly preferred by patients and 
clinicians. Based on our current understandings of 
biochemical and physiological aspects of absorption and 
metabolism, many drugs, cannot be delivered effectively 
through the conventional oral route, because after 
administration are subjected to pre-systemic clearance 
extensively in liver, which often leads to a lack of 
significant correlation between membrane permeability, 
absorption, and bioavailability
5
. Difficulties associated 
with parenteral delivery and poor oral availability 
promoted the impetus for exploring alternative routes for 
the delivery of such drugs. Consequently, other 
absorptive mucosae are considered as potential sites for 
drug administration. Transmucosal routes of drug 
delivery (i.e., the mucosal linings of the nasal, rectal, 
vaginal, ocular, and oral cavities) offer distinct 
advantages over peroral administration for systemic 
effect. Among the various transmucosal routes, buccal 
mucosa has an excellent accessibility, an expanse of 
smooth muscle and relatively immobile mucosa, hence 
suitable for administration of controlled release dosage 
forms. Additionally, buccal drug delivery has a high 
patient acceptability compared to other non-oral 
transmucosal routes of drug administration. Direct access 
to the systemic circulation through the internal jugular 
vein avoids acid hydrolysis in the gastrointestinal (GI) 
tract and bypasses drugs from the hepatic first pass 
metabolism leading to high bioavailability. Moreover, 
rapid cellular recovery of the buccal mucosa is other 
advantage of this route
6
. Disadvantages of drug delivery 
by this route are the low permeability of the buccal 
membrane
7
, specifically when compared to the 
sublingual membrane 
8
, and a smaller surface area. 
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ABSTRACT 
Buccal mucosa is the preferred site for both systemic and local drug action. The mucosa has a rich blood supply and it 
relatively permeable. The buccal region of the oral cavity is an attractive target for administration of the drug of choice, 
particularly in overcoming deficiencies associated with the latter mode of administration. Problems such as first-pass 
metabolism and drug degradation in the gastrointestinal environment can be circumvented by administering the drug via the 
buccal route. Moreover, rapid onset of action can be achieved relative to the oral route and the formulation can be removed if 
therapy is required to be discontinued. It is also possible to administer drugs to patients who unconscious and less co-operative. 
In buccal drug delivery systems mucoadhesion is the key element so various mucoadhesive polymers have been utilized in 
different dosages form. Mucoadhesion may be defined as the process where polymers attach to biological substrate or a 
synthetic or natural macromolecule, to mucus or an epithelial surface. When the biological substrate is attached to a mucosal 
layer then this phenomenon is known as mucoadhesion. The substrate possessing bioadhesive polymer can help in drug 
delivery for a prolonged period of time at a specific delivery site.  Both natural and synthetic polymers are used for the 
preparation of mucoadhesive buccal patches.  However, this review article provides a current status of buccal drug delivery of 
patches (films) along with formulation development and characterization of mucoadhesive buccal patches. 
Keywords: Buccal, Mucoadhesive Polymer, Buccal formulations, Buccal patch 
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Buccal administration of drugs provides a convenient 
route of administration for both systemic and local drugs 
actions
9
. Over the last two decades mucoadhesion has 
become of interest for its potential for localized drug 
delivery, by retaining a dosage form at the site of action 
(e.g. within the gastrointestinal tract) or systemic 
delivery by retaining a formulation an intimate contact 
with the absorption site (e.g. buccal cavity
10 
.Recently 
various Mucoadhesive devices, including tablets, films, 
patches, disks, strips, ointments and gels, have recently 
been developed. However, buccal patch offer greater 
flexibility and comfort than adhesive tablets. In addition, 
a patch can circumvent the problem of the relatively 
short residence time of oral gels on mucosa, since the 
gels are easily washed away by saliva. Buccal route of 
drug delivery provides direct access to the systemic 
circulation through the jugular vein by passing the 
hepatic first pass metabolism leading to high 
bioavailability.
11
 The term bioadhesion is typically used 
to describe the adhesion between polymer either 
synthetic or natural to soft tissue.  
In instances when bond is formed between mucus 
membrane and polymer the term mucoadhesion is used. 
Mucus membrane is one, in which the goblet cells are 
present for the secretion of mucus which is composed of 
glycoprotein mucin. Buccal mucosa presents a relatively 
smooth and immobile surface for the placement of 
Mucoadhesive dosage form. The amount of drug that can 
be incorporated is limited by the size limitation of the 
buccal dosage form. In general, a drug with a daily 
requirement of 25 mg or less is suitable for buccal 
delivery. Drug with short half-life, requiring sustained or 
controlled release showing poor aqueous solubility and 
which is sensitive to enzymatic degradation, may be 
successfully delivered across the buccal mucosa. Buccal 
delivery system is found to be the most promising 
because buccal mucosa itself provides a protecting 
covering for the underlying tissues acting as a physical 
barrier against toxins and microorganism
12,13
. Buccal 
delivery system provides easy administration thereby 
increasing patient compliance. Drug is easily 
administered and extinction of therapy in emergency can 
be facilitated .It can be administered in unconscious and 
trauma patients .Large contact surface of the oral cavity 
contributes to rapid and extensive drug absorption. 
Because of the high permeability and rich blood supply 
transport via the sublingual route results in a rapid onset 
of action
14
.  
Mucoadhesive buccal drug delivery system
15, 16  
Drug delivery via the mucosal membrane of the oral 
cavity can be divided into following:  
 Sublingual delivery: - Drug administration via 
sublingual mucosa to the systemic circulation. 
 Buccal delivery: - Drug administration via buccal 
mucosa to the systemic circulation. 
 Local delivery: - Drug administration via 
bioadhesive sytem either to the palate or the cheek. 
 
 
ADVANTAGES OF MUCOADHESIVE BUCCAL 
DRUG DELIVERY SYSTEM
17-22 
Mucoadhesive via buccal route offers following 
advantages: -  
 Ease of drug administration and termination of drug 
action can be easily accomplished. 
 Permits localization or retention of the drug to the 
specified area of oral cavity for extended period of 
time. 
 Bypass hepatic first pass metabolism. 
 Drugs with poor bioavailability owing to the high 
first pass metabolism can be administered 
conveniently. 
 Ease of drug administration to unconscious patients. 
 Water content of saliva is being capable to ensure 
drug dissolution. 
Limitation of buccal drug administration
17-22 
There is certain limitation via drug administered through 
buccal route: -  
 Drugs with ample dose are often difficult to be 
administered. 
 Possibility of the patients to swallow the tablets 
being forgotten. 
 Eating and drinking may be restricted till the end of 
drug release. 
 This route is unacceptable for those drugs, which are 
unstable at pH of buccal environment. 
 This route cannot administer drugs, which irritate 
the mucosa or have a bitter or unpleasant taste. 
 Limited surface area is available for absorption.   
BUCCAL PATCHES ARE OF TWO TYPES 
23
 
(a)In matrix type-The drug is homogeneously dispersed 
in hydrophilic or lipophilic polymer matrix and the 
medicated polymer is then moulded into medicated disc 
with a defined surface area. 
(b)In reservoir type-The buccal patch designed in a 
reservoir system contains a cavity for the drug and 
additives separate from the adhesive. An impermeable 
backing is applied to in the mouth and to prevent drug 
loss. 
BIOADHESION 
24, 25, 26 
‘Bioadhesive’ is defined as a substance that is capable of 
interacting with biological material and being retained on 
them or holding them together for extended period of 
time. Bioadhesive are classified into three types. 
 Bioadhesion between biological layers without 
involvement of artificial materials. Cell diffusion 
andcell aggregation are good examples. 
  Bioadhesion can be represented by cell adhesion 
into culture dishes or adhesion to a variety of 
substances including metals, woods and other 
synthetic materials. 
 Adhesion of artificial substances to biological 
substrate such as adhesion of polymer to skin or 
other soft tissue. 
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MECHANISM OF BIOADHESION 
27, 28, 29
 
For bioadhesion to occur, three stages are involved: 
 An intimate contact between a bioadhesive and a 
membrane either from a good wetting of the 
bioadhesive and a membrane or from the swelling of 
bioadhesive. 
 Penetration of the bio-adhesive into the tissue takes 
place. 
 Inter penetration of the chains of the bioadhesive 
with mucous takes place. Low chemical bonds can 
then settle. 
The bonding between the mucus and the biological 
substance occurs chiefly through both physical and 
chemical interactions results from enlargement of the 
adhesive material and chemical bonds due to electrostatic 
interaction, hydrophobic interactions, hydrogen bonding 
and dispersion forces. 
BIOADHESIVE POLYMER 
The first step in the development of buccoadhesive 
dosage forms is the selection and Characterization of 
appropriate bio adhesive polymers in the formulation. 
Bio adhesive polymers play a major role in 
buccoadhesive drug delivery systems of drugs. Polymers 
are also used in matrix devices in which the drug is 
embedded in the polymer matrix, which control the 
duration of release of drugs
30
 .Bio adhesive polymers are 
from the most diverse class and they have considerable 
benefits upon patient health care and treatment
31
. The 
drug is released into the mucous membrane by means of 
rate controlling layer or core layer. Bio adhesive 
polymers which adhere to the mucin/ epithelial surface 
are effective and lead to significant improvement in the 
oral drug delivery
32
. 
AN IDEAL POLYMER FOR BUCCOADHESIVE 
DRUG DELIVERY SYSTEMS SHOULD HAVE 
FOLLOWING CHARACTERISTICS
33
  
It should be inert and compatible with the environment. 
 The polymer and its degradation products should be 
non-toxic absorbable from the mucous layer. 
 It should adhere quickly to moist tissue surface and 
should possess some site specificity. 
 The polymer must not decompose on storage or 
during the shelf life of the dosage form. 
 The polymer should be easily available in the market 
and economical. 
 It should allow easy incorporation of drug in to the 
formulation. 
CRITERIA FOLLOWED IN POLYMER 
SELECTION 
 It should form a strong non covalent bond with the 
mucine/epithelial surface. 
 It must have high molecular weight and narrow 
distribution. 
 It should be compatible with the biological 
membrane.
 
Table1: Bio adhesive polymers in pharmaceutical applications
34 
Criteria Categories Examples 
 
 
 
 
 
 
 
 
Sources  
 
 
Semi natural/ Natural 
Agarose, chitosan, gelatin, Hyaluronic acid, Various gums (guar gum, xanthan, 
gellan, carragenan, pectin and sodium 
alginate). 
 
 
 
 
 
Synthetic 
Cellulose derivatives: [CMC, thiolated CMC, NaCMC, HEC, HPC, HPMC,MC.] 
Poly(acrylic acid)-based polymers: 
[CP, PC, PAA, polyacrylates, 
poly(methyl vinyl ether-co-methacrylic acid), poly(2- hydroxy ethyl 
methacrylate),poly(acrylic acidco-ethyl hexyl acrylate), poly(methacrylate), 
poly(isobutylcyanoacrylate), copolymer of acrylic acid and PEG]. 
Others: polyoxyethylene, PVA, PVP, 
thiolated Polymers. 
 
BACKING MEMBRANE  
Backing membrane plays a major role in the attachment 
of bioadhesive devices to the mucus membrane. The 
materials used as backing membrane should be inert, and 
impermeable to the drug and penetration enhancer. Such 
impermeable membrane on buccal bioadhesive patches 
prevents the drug loss and offers better patient 
compliance. The commonly used materials in backing 
membrane 
35
 include carbopol, magnesium stearate, 
HPMC, HPC, CMC, polycarbophil etc . 
PERMEATION ENHANCERS:  
Substances that facilitate the permeation through buccal 
mucosa are referred as permeation enhancers. Selection 
of enhancer and its efficacy depends on the 
physicochemical properties of the drug, site of 
administration, nature of the vehicle and other 
Excipients. Table 2   
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Table 2: Examples of permeation enhancers with mechanism
 34
 
Category Examples Mechanism(s) 
Surfactants 
and Bile Salts 
Surfactants and Bile Salts, Sodium dodecyl 
sulphate, Sodium lauryl sulphate, Polysorbate 80 
Acting on the components at tight junctions 
Increasing the fluidity of lipid bilayer membrane; 
Fatty Acids Oleic acid, Cod liver oil, Capric acid, Lauric acid Increasing the fluidity of lipid bilayer membrane. 
Polymers and 
Polymer Der. 
Chitosan, Trimethyl chitosan 
Chitosan-4- thiobutylamide 
Increasing the fluidity of lipid bilayer membrane; 
Increased retention of drug at mucosal surface. 
Others Ethanol, Azone, Octisalate, Padimate, Menthol Acting on the components at tight junctions; 
Increasing the fluidity of lipid bilayer membrane 
 
MANUFACTURING METHODS OF BUCCAL 
PATCHES/ FILMS:
 
Manufacturing processes involved in making 
mucoadhesive buccal patches/films, namely solvent 
casting, hot melt extrusion and direct milling. 
 Solvent casting: In this method, all patch excipients 
including the drug co-dispersed in an organic solvent and 
coated onto a sheet of release liner. After solvent 
evaporation a thin layer of the protective backing 
material is laminated onto the sheet of coated release 
liner to form a laminate that is die-cut to form patches of 
the desired size and geometry
36
. 
Direct milling: In this, patches are manufactured 
without the use of solvents. Drug and excipients are 
mechanically mixed by direct milling or by kneading, 
usually without the presence of any liquids. After the 
mixing process, the resultant material is rolled on a 
release liner until the desired thickness is achieved. The 
backing material is then laminated as previously 
described.
37
 While there are only minor or even no 
differences in patch performance between patches 
fabricated by the two processes, the solvent-free process 
is preferred because there is no possibility of residual 
solvents and no associated solvent-related health issues
38
. 
Hot melt extrusion of films: In hot melt extrusion blend 
of pharmaceutical ingredients is molten and then forced 
through an orifice to yield a more homogeneous material 
in different shapes such as granules, tablets, or films. Hot 
melt extrusion has been used for the manufacture of 
controlled release matrix tablets, pellets and granules, as 
well as oral disintegrating films.  
Solid dispersion extrusion: 
In this immiscible components are extrude with drug and 
then solid dispersions are prepared. Finally the solid 
dispersions are shaped in to films by means of dies. 
 Semisolid casting:  
In the semisolid casting method firstly a solution of 
water soluble film forming polymer is prepared .The 
resulting solution is added to a solution of acid insoluble 
polymer (cellulose acetate phthalate, cellulose acetate 
butyrate) which was prepared in ammonium or sodium 
hydroxide. Then appropriate amount of plasticizer is 
added so that a gel mass is obtained. Finally the gel mass 
is casted in to films or ribbons using heat controlled 
drums. Thickness of the film is about 0.015-0.05 inches. 
The ratio of the acid insoluble forming polymer should 
be 1:4. 
  
Rolling method: 
 In this rolling method solution or suspension containing 
drug is rolled on a carrier. The solvent is mainly water 
and mixture of water and alcohol. The film is dried on 
rollers and cut in to desired shapes and sizes.  
EVALUATIONS OF BUCCAL PATCH: 
 Surface pH: Buccal patches are left to swell for 2 hrs 
on the surface of an agar plate. The surface pH is 
measured by means of a pH paper placed on the surface 
of the swollen patch.
39-40 
 Thickness measurements: The thickness of each film 
is measured at five different locations (centre and four 
corners) using an electronic digital micrometer
41
. 
 Swelling study: Buccal patches are weighed 
individually (designated as W1), and placed separately in 
2% agar gel plates, incubated at 37°C ± 1°C, and 
examined for any physical changes. At regular 1- hr time 
intervals until 3 hours, patches are removed from the gel 
plates and excess surface water is removed carefully 
using the filter paper 
42
. The swollen patches are then 
reweighed (W2) and the swelling index (SI) are 
calculated using the following formula. 
SI= (W2-W1)/W1× 100. 
 Folding endurance: The folding endurance of patches 
is determined by repeatedly folding 1 patch at the times 
without breaking
43
. 
 Thermal analysis study: Thermal analysis study is 
performed using differential scanning calorimeter (DSC). 
 Morphological characterization: Morphological 
characters are studied by using scanning electron 
microscope (SEM). 
 Permeation study of buccal patch: The receptor 
compartment is filled with phosphate buffer pH 6.8, and 
the hydrodynamics in the receptor compartment is 
maintained by stirring with a magnetic bead at 50 rpm. 
Samples are withdrawn at predetermined time intervals 
and analyzed for drug content 
44
. 
 In vitro drug release: The United States Pharmacopeia 
(USP) XXIII-B rotating paddle method is used to study 
the drug release from the bilayered and multilayered 
patches. The dissolution medium consisted of phosphate 
buffer pH 6.8. The release is performed at 37°C ± 0.5°C, 
with a rotation speed of 50 rpm. The backing layer of 
buccal patch is attached to the glass disk with instant 
adhesive material. The disk is allocated to the bottom of 
the dissolution vessel. Samples (5 ml) are withdrawn at 
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predetermined time intervals and replaced with fresh 
medium. The samples filtered through whatman filter 
paper and analyzed for drug content after appropriate 
dilution. The in-vitro buccal permeation through the 
buccal mucosa (sheep and rabbit) is performed using 
Keshary-Chien /Franz type glass diffusion cell at 37°C± 
0.2°C. Fresh buccal mucosa is mounted between the 
donor and receptor compartments. The buccal patch is 
placed with the core facing the mucosa and the 
compartments clamped together. 
 Ex-vivo mucoadhesion time: The ex-vivo 
mucoadhesion time performed after application of the 
buccal patch on freshly cut buccal mucosa (sheep and 
rabbit). The fresh buccal mucosa is tied on the glass 
slide, and a mucoadhesive patch is wetted with 1 drop of 
phosphate buffer pH 6.8 and pasted to the buccal mucosa 
by applying a light force with a fingertip for 30 secs. The 
glass slide is then put in the beaker, which is filled with 
200 ml of the phosphate buffer pH 6.8, is kept at 37°C ± 
1°C. After 2 minutes, a 50-rpm stirring rate is applied to 
simulate the buccal cavity environment, and patch 
adhesion is monitored for 12 hrs. The time for changes in 
color, shape, collapsing of the patch and drug content is 
noted
45
.  
 Measurement of mechanical properties: Mechanical 
properties of the films (patches) include tensile strength 
and elongation at break is evaluated using a tensile tester. 
Film strip with the dimensions of 60 x 10 mm and 
without any visual defects cut and positioned between 
two clamps separated by a distance of 3 cm. Clamps 
designed to secure the patch without crushing it during 
the test, the lower clamp held stationary and the strips are 
pulled apart by the upper clamp moving at a rate of 2 
mm/sec until the strip break. The force and elongation of 
the film at the point when the strip break is recorded. The 
tensile strength and elongation at break values are 
calculated using the formula. 
T = m x g/ b x t Kg/mm2 
Where, 
M - is the mass in gm, g - is the acceleration due to 
gravity 980 cm/sec 2, B - is the breadth of the specimen 
in cm, T - is the thickness of specimen in cm Tensile 
strength (kg/mm2) is the force at break (kg) per initial 
cross- sectional area of the specimen (mm2). 
Weight variation- The three disks of 1cm2 was cut and 
weight individually on electronic balance for weight 
variation test and the average weights were calculated. 
The test was done to check the uniformity of weight and 
thus check the batch to batch variation.
cls 
Thickness- Thickness of the patch was measured by 
using vernier callipers with atleast count 0.001mm.The 
thickness uniformity was measured at five different 
points and average reading was taken. 
Buccal absorption test 
A method 
46
 for the measurement of the developed a 
method to measure the kinetics of the drug absorption by 
swirling a 25 ml sample of the test solution for 15 min by 
human volunteers followed by the expulsion of the 
solution. The amount of the drug remaining in the 
expelled volume is then determined to assess the amount 
of drug absorbed. The drawbacks of this method are 
inability to localize the drug solution within a specific 
site of the oral cavity, accidental swallowing of a portion 
of the sample solution and the salivary dilution of the 
drug. 
Modified beckett's test 
The test has been modified 
47 
by addition of phenol red as 
a marker for drug dilution by saliva secretion as well as 
for accidental swallowing of the drug solution. The 
‘Schurmann and Turner Test’ has also been modified48 
by taking a small sample of the solution in the oral cavity 
every few minutes, without removal of the residual 
solution. In this way he was able to study kinetics of the 
absorption in a single test for 15–20 minutes.  
CONCLUSION  
Buccal adhesive systems offer innumerable advantages 
in terms of accessibility, administration and withdrawal, 
retentivity, low enzymatic activity, economy and high 
patient compliance. Buccal region provides a convenient 
route of administration for both local and systemic drug 
actions. Buccal adhesive systems offer innumerable 
advantages in term of accessibility, administration and 
withdrawal, retentivity, low enzyme activity, economy 
and high patients compliance. Buccal drug delivery is a 
promising area for continued research with the aim of 
systemic delivery of orally inefficient drugs as well as a 
feasible and attractive alternative for non-invasive 
delivery of potent peptide and protein drug molecules. 
Adhesions of these drug delivery devices to mucosal 
membranes lead to an increased drug concentration 
gradient at the absorption site and therefore improve 
bioavailability of systemically delivered drugs. In 
addition, buccal adhesive dosage forms have been used 
to target local disorders at the mucosal surface (e.g., 
mouth ulcers), to reduce the overall required dosage and 
minimize side effects that may be caused by systemic 
administration of drugs. Investigations are continuing 
beyond traditional polymer networks to find other 
innovative drug transport systems. Currently solid 
dosage forms, liquids, spray and gels applied to oral 
cavity are commercially successful. The future direction 
of buccal adhesive drug delivery lies in vaccine 
formulations and delivery of small proteins/peptides. 
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